Checkpoint inhibitor-associated autoimmune diabetes (CIADM) is a distinct pathophysiologic entity from type 1 diabetes and represents a new model for autoimmune beta-cell failure, according to study results published in The Journal of Endocrinology & Metabolism. Although immune checkpoint inhibitors can improve survival of patients with various advanced cancers, one of the rare immune-related adverse endocrine […]
